About Personalis
Personalis is a publicly listed company based in Menlo Park (United States) founded in 2011. Genomic sequencing and diagnosis software is provided for healthcare. Personalis has raised $87.3 million across 5 funding rounds from investors including Merck, Lightspeed Venture Partners and Leland Stanford Junior University. The company has 229 employees. Its website personalis.com draws about 15 thousand monthly visits. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Diversified. Its legal entity is PERSONALIS INC. Its competitors include Foundation Medicine, Tempus and Veritas Genetics; 3 of its 3 listed competitors have raised funding.
Company details
Personalis was founded in 2011 and is headquartered in Menlo Park, United States. Services in the healthcare sector focus on genomic sequencing of DNA, RNA, augmented exome, and targeted transcriptome. Products such as the ImmunoID NeXT platform support precision oncology through analytical algorithms for immune checkpoints and related information. Additional offerings include RepertoireID for tumor sample analysis, ImmunogenomicsID, and NeoantigenID.
- Headquarters Menlo Park, United States
- Employees 229
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website personalis.com
- Social LinkedIn X
- Legal Name Personalis, Inc.
- Annual Revenue$69.65 M (USD)-17.69as on Dec 31, 2025
- Net Profit-$81.27 M (USD)0.02as on Dec 31, 2025
- EBITDA-$78.01 M (USD)-36.08as on Dec 31, 2025
- Total Equity Funding$87.3M (USD)
in 5 rounds
- Latest Funding Round$50M (USD), Post-IPO
Dec 2024
- InvestorsMerck
& 5 more
- Employee Count229
Funding Insights of Personalis
Personalis has successfully raised a total of $87.3M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87.3M
- Total Rounds 5
- Last Round Post-IPO — $50M
- First Round $20M
(Oct 2011)
- Investors Count 6
All 5 funding rounds of Personalis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $50M | Post-IPO | – | – | |
| Jul 2017 | $12.23M | Series C | – | – | – |
| Dec 2014 | $33M | Series C | – | Lightspeed Venture Partners | |
| Oct 2013 | $22.08M | Series B | – | Abingworth | |
| Oct 2011 | $20M | Series A | – | Abingworth, Lightspeed Venture Partners | – |
6 investors in total: 6 institutional.
Investors in Personalis
Personalis has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Lightspeed Venture Partners and Leland Stanford Junior University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Venture capital investments are managed in technology and healthcare sectors by this firm. | mdv.com | |||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom | |
Offers wealth management and investment services to clients and professionals. | 1925 | wellingtonshields.com | New York, United States | |
Various courses and degrees across diversified streams are offered. | 1876 | stanford.edu | United States |
Investor details for Personalis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Personalis
96 people are tracked at Personalis (46 in leadership, 5 in board & advisors, 45 in team); the tracked headcount is 229.
| Name | Role | Group |
|---|---|---|
Carol Taubman | Associated Director, Accounting | Leadership |
Richard Chen | Chief Medical Officer & VP, R&D | Leadership |
Ken Brunt | VP, Client Experience | Leadership |
Amanda Castle | Director, Biopharma Business Development - Europe | Leadership |
Ashish Kheterpal | Chief Information Officer | Leadership |
Donald Brown | Vice President Operations | Leadership |
Stephen Fairclough | VP, Informatics | Leadership |
Christopher Mallo | Associate Director, CLIA Laboratory Operations | Leadership |
Doug Zeman | Associate Director Of Scientific Computing & IT | Leadership |
Stanley Welle | Director, Strategic Business Development | Leadership |
Nitin Udar | Sr Director Clinical Affairs And Companion Diagnsotics | Leadership |
Marissa Runes | Associate Director Of Document Control | Leadership |
Juan-Sebastian Saldivar | Laboratory Medical Director | Leadership |
Christelle Johnson | Director, Field Applications Scientist | Leadership |
Yi Chen | Regional Director, Scientific And Medical Affairs (west Coast) | Leadership |
Winnie Chiu | Sr. Director - Biopharma Business Development, Western Region | Leadership |
Desmond Win | Director, Financial Planning And Analysis | Leadership |
Christopher Hall | CEO | Leadership |
Aaron Tachibana | CFO & COO | Leadership |
Kar-Mun Wong | Vp, Corporate Controller | Leadership |
76 more people are available in the full profile.
Complete people profiles for Personalis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Personalis
Personalis is a publicly listed company on the NASDAQ with ticker symbol PSNL in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jun 2019
- Listed onNASDAQ: PSNL
- Listed entityPersonalis, Inc.
- Exchange sectorHealth services
- ISINUS71535D1063
- Share price$15.85 (+0.32% on the day) · 2026-10-13
- Market capitalisation$1.69B
- EPS (diluted, trailing year)$-1.09
- Volume (last session)3,817,337
Financials of Personalis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $69.7M | -$81.3M | -$78.0M |
| 2024 | $84.6M | -$81.3M | -$57.3M |
| 2023 | $73.5M | -$108.3M | -$85.0M |
| 2022 | $65.0M | -$113.3M | -$102.7M |
| 2021 | $85.5M | -$65.2M | -$56.4M |
Detailed financial statements for Personalis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Personalis
4 dated milestones of Personalis across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Personalis is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Personalis
Personalis has 3 listed competitors in our database, 3 of them funded. They include Foundation Medicine, Tempus and Veritas Genetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| tempus.com | 2015 | Chicago, United States | $1.05B | 772 | AI-based precision medicine solutions for oncology are provided. | |
| veritasgenetics.com | 2014 | Danvers, United States | $53.38M | 14 | Genetic testing products for health risks and traits are offered. |
Detailed competitors of Personalis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Personalis
The website of Personalis (personalis.com) receives about 15K visits a month and ranks #748,077 among all websites worldwide, #873 in Biotechnology and Pharmaceuticals.
- Monthly visits15K
▼ 30.8% vs previous month
- Unique visitors5.4K
per month
- Global rank#748,077
among all websites
- Category rank#873
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit10.4
- Average visit9 min 07 sec
- DevicesDesktop 78% · Mobile 22%
Websites whose visitors overlap most with Personalis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oricpharma.com | 100% | 10.7K | #1,871,764 | View details | |
| bio-itworld.com | 92% | #1,672,238 | View details | ||
| numedii.com | 87% | View details | |||
pharmacompliancemonitor.com | pharmacompliancemonitor.com | 86% | – | ||
| hgsi.com | 86% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Personalis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Personalis (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Personalis
Complete news archive for Personalis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Personalis
Personalis was founded in 2011.
Personalis is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Personalis is a funded company, having raised a total of $87.3M across 5 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Oct 2011.
Personalis has 229 employees.
Annual revenue of Personalis is $69.65M as on Dec 31, 2025.
Personalis was founded in 2011 and is headquartered in Menlo Park, United States. Services in the healthcare sector focus on genomic sequencing of DNA, RNA, augmented exome, and targeted transcriptome. Products such as the ImmunoID NeXT platform support precision oncology through analytical algorithms for immune checkpoints and related information. Additional offerings include RepertoireID for tumor sample analysis, ImmunogenomicsID, and NeoantigenID.
Personalis's top competitors include Tempus, Foundation Medicine and Veritas Genetics.
Yes, Personalis is publicly traded on NASDAQ under the ticker symbol PSNL.
Personalis has 6 investors. Key investors include Merck, Lightspeed Venture Partners, Leland Stanford Junior University, Abingworth, and Mohr Davidow Ventures.
Personalis operates through Personalis Inc.